Hypertension after kidney transplantation: An important, but still neglected issue

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2310-2311

  Marasà, Maddalena ^a   Remuzzi, Giuseppe ^a   Cravedi, Paolo ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; GRAFT FAILURE; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; NOTE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 81355142705     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834d7815     Document Type: Note

References (20)

1. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603-611.
2. Kasiske BL, Anjum S, Shah R, Skogen J, Kandaswamy C, Danielson B, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071-1081.
3. Campistol JM, Romero R, Paul J, Guitierrez-Dalmau A. Epidemiology of arterial hypertension in renal transplant patients: changes over the last decade. Nephrol Dial Transplant 2004; 19 (Suppl 3):iii62-iii66.
4. Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3:822-828.
5. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000; 283:633-638.
6. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 2008; 53:217-222.
7. Hillebrand U, Suwelack BM, Loley K, Lang D, Reuter S, Amler S, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009; 22:1073-1080.
8. Opelz G, Döhler B, Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5:2725-2731.
9. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
10. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
11. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1-S290.
12. Chatzikyrkou C, Menne J, Gwinner W, Schmidt BM, Lehner F, Blume C, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens 2011; 29:2283-2294.
13. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661.
14. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Working Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3):S1-S155.
15. Cravedi P, Perico N, Remuzzi G. Nonimmune interventions to protect kidney allograft in the long term. Kidney Int 2010; 119:S71-S75.
16. Remuzzi G, Benigni A, Remuzzi A. Mechanism of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:288-296.
17. Nauta FL, Bakker SJ, van Oeveren W, Navis G, van der Heide JJ, van Goor H, et al. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis 2001; 57:196-202.
18. Artz MA, Hilbrands LB, Borm G, Assmann KJ, Wetzels JF. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19:2852-2857.
19. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
20. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889-899.